Literature DB >> 31566017

Can CDK4/6 inhibitors cause fatal lung injury?

Khalid A Jazieh1, G Thomas Budd2, Nancy Dalpiaz2, Jame Abraham2.   

Abstract

Entities:  

Keywords:  Abemaciclib; Breast Cancer; Palbociclib; Pneumonitis; Toxicity

Mesh：

Substances：

Year:  2019        PMID： 31566017     DOI： 10.1080/14737140.2019.1674651

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  9 in total

1.  CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice.

Authors:  Yongfeng Zhang; Ben Jin; Haiyan D Miller; Dongxia Ge; Xin Zhang; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

2.  Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment.

Authors:  Lu Turković; Luka Bočkor; Oscar Ekpenyong; Tajana Silovski; Mila Lovrić; Slaven Crnković; Biljana Nigović; Miranda Sertić
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-16

3.  AMPA Receptor Encephalitis in a Patient With Metastatic Breast Cancer Receiving Palbociclib: A Case Report.

Authors:  Elizabeth Matthews; Barrie Schmitt; Michlene Passeri; Christopher Mizenko; Karen Orjuela; Amanda Piquet
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-06

4.  CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis.

Authors:  Anna Birnhuber; Bakytbek Egemnazarov; Valentina Biasin; Ehsan Bonyadi Rad; Malgorzata Wygrecka; Horst Olschewski; Grazyna Kwapiszewska; Leigh M Marsh
Journal:  Respir Res       Date:  2020-07-02

5.  Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus.

Authors:  Christos Papageorgiou; Flora Zagouri; Konstantinos Tampakis; Rebecca Georgakopoulou; Efstathios Manios; Pavlos Kafouris; Georgios Benetos; Iosif Koutagiar; Constantinos Anagnostopoulos; Meletios A Dimopoulos; Konstantinos Toutouzas
Journal:  Front Cardiovasc Med       Date:  2021-02-23

6.  Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.

Authors:  Uzma S Asghar; Ruhi Kanani; Rebecca Roylance; Sibylle Mittnacht
Journal:  JCO Precis Oncol       Date:  2022-01

7.  Expression, purification and characterisation of a human anti-CDK4 single-chain variable fragment antibody.

Authors:  Jialiang Zhao; Jingjing Xu; Tianbin Yang; Xinze Yu; Cheng Cheng; Tong Zhang; Ze Ren; Na Li; Fang Yang; Guiying Li
Journal:  BMC Biotechnol       Date:  2021-12-20       Impact factor: 2.563

8.  CDK 4/6 inhibitor induced lung injury: a case report and review of literature.

Authors:  Namrata Mathew; Anjana Joel; Anand George Andrews; Ajoy Oommen John; Ashish Singh
Journal:  Ecancermedicalscience       Date:  2021-06-07

9.  Ribociclib-Induced Pneumonitis: A Case Report.

Authors:  Ghada Algwaiz; Ahmed Ali Badran; Mahmoud A Elshenawy; Taher Al-Tweigeri
Journal:  Breast Care (Basel)       Date:  2020-07-08       Impact factor: 2.268
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.